Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Daiichi Sankyo Buys Shanghai Xinshengyuan Pharma

publication date: Apr 20, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Daiichi Sankyo's China subsidiary has gained control of Shanghai Xinshengyuan Pharmaceutical Group Medicine & Chemical Reagents Sales Co., a company that imports Ranbaxy's generic drug portfolio into China. Daiichi and Ranbaxy are already partners. In 2008, Daiichi Sankyo paid $4.6 billion for a controlling interest in Ranbaxy, adding generic drugs to Daiichi Sankyo's portfolio of innovative drugs. By buying Xinshengyuan, Daiichi gains control of its partner's products in China. More details....

Stock Symbols: (TO: 4658) (BSE: 500359)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors